122 related articles for article (PubMed ID: 38155081)
21. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
[TBL] [Abstract][Full Text] [Related]
22. Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer.
Rajwa P; Pfister D; Rieger C; Heidenreich J; Drzezga A; Persigehl T; Shariat SF; Heidenreich A
Prostate; 2023 Mar; 83(4):385-391. PubMed ID: 36564936
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
[TBL] [Abstract][Full Text] [Related]
24. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
25. Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [
Grubmüller B; Jahrreiss V; Huebner N; Mitterhauser M; Stangl-Kremser J; Grubmüller KH; Baltzer P; Hacker M; Goldner G; Shariat SF; Rasul S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):439-447. PubMed ID: 32994534
[TBL] [Abstract][Full Text] [Related]
26.
Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study.
Ucar T; Gunduz N; Demirci E; Culpan M; Gunel H; Kir G; Atis RG; Yildirim A
Prostate; 2022 Nov; 82(15):1462-1468. PubMed ID: 35915579
[TBL] [Abstract][Full Text] [Related]
28. 3-Year Freedom from Progression After
Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
[No Abstract] [Full Text] [Related]
29. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):558-567. PubMed ID: 37736808
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
31. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Baas DJH; Schilham M; Hermsen R; de Baaij JMS; Vrijhof HJEJ; Hoekstra RJ; Sedelaar JPM; Küsters-Vandevelde HVN; Gotthardt M; Wijers CHW; van Basten JP; Somford DM
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):65-70. PubMed ID: 34471231
[TBL] [Abstract][Full Text] [Related]
32. Changes in Management After
Ng M; Guerrieri M; Wong LM; Taubman K; Sutherland T; Benson A; Byrne G; Koschel S; Yap K; Starmans M; Ong G; Macleod C; Foo M; Chao M
J Nucl Med; 2022 Sep; 63(9):1343-1348. PubMed ID: 35058320
[TBL] [Abstract][Full Text] [Related]
33. Prospective evaluation of the performance of [
Abufaraj M; Grubmüller B; Zeitlinger M; Kramer G; Seitz C; Haitel A; Baltzer P; Hacker M; Wadsak W; Pfaff S; Wiatr T; Mitterhauser M; Shariat SF; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2169-2177. PubMed ID: 31254037
[TBL] [Abstract][Full Text] [Related]
34. Development and external validation of a multivariable [
Muehlematter UJ; Schweiger L; Ferraro DA; Hermanns T; Maurer T; Heck MM; Rupp NJ; Eiber M; Rauscher I; Burger IA
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3137-3146. PubMed ID: 37261472
[TBL] [Abstract][Full Text] [Related]
35.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
36. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
37. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of
Dong L; Zhu Y; Xin M; Dong B; Pan J; Liu J; Amend SR; Xue W; Pienta KJ; Rowe SP
Med Oncol; 2020 Sep; 37(10):89. PubMed ID: 32920666
[TBL] [Abstract][Full Text] [Related]
39. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
40. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
